



## **Board of Directors and management of Prostatype Genomics AB enter into agreements regarding lock up**

*Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that members of the Board and management of the Company have entered into agreements regarding prolonged lock up of their holdings in the Company. The lock up refers to 100 percent of each of the parties’ holdings, for a period lasting until the 30<sup>th</sup> of April 2022.*

In connection with the IPO of Prostatype, members of the Board, as well as management and other shareholders entered into agreement regarding lock up. These agreements expire on the 3<sup>rd</sup> of November 2021, which is 12 months after the first day of trading in Prostatype’s shares and warrants on Nasdaq First North Growth Market.

The Board of Directors as well as management have now, based on that the original agreements will expire shortly, entered into prolonged agreements regarding lock up. The parties who have entered into the agreements are Creathor Venture Fund III (SCS) SICAR, Creathor Venture Fund III Parallel (SCS) SICAR, Board members Håkan Englund, Michael Häggman, Anders Lundberg, CEO Fredrik Persson and CFO Michael af Winklerfelt. Together, these shareholders own approximately 30 percent of the total shares in the Company.

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-10-2021 10:00 CET.

### **Press contact**

**Nicklas Rosendal**

nicklas.rosendal@prostatypegenomics.com

### **Certified Advisor**

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, [ca@skmg.se](mailto:ca@skmg.se)